The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.
Abstract
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7)”
From Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test (2021) · cites this paper as [7]
In the citing paper
“dysregulated α-cell release of glucagon, manifest as increased fasting glucagon concentrations and a failure to adequately suppress glucagon release following meal ingestion, contributes to the development of hyperglycaemia34.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [34]
Citations
Cites
Items 201–313 of 313
Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency.
Cherrington, A. D., LILJENQUIST, J. E., Shulman, G. I., Williams, P. E., & LACY, W. W. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.3.e263 · Cited by 77
The Amino Acid Sequence of Glucagon
BROMER, W. W., Sinn, L. G., Staub, A., & Behrens, O. K. (1957) · Diabetes · doi:10.2337/diab.6.3.234 · Cited by 77
Starke, A., Imamura, T., & Unger, R. H. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112784 · Cited by 71
Glucagon immunoreactivity in plasma from normal and dystrophic mice
Ahr�n, B., & Lundquist, I. (1982) · Diabetologia · doi:10.1007/bf00281302 · Cited by 68
Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs
Hruby, V. J. (1982) · Molecular and Cellular Biochemistry · doi:10.1007/bf00573846 · Cited by 67
Gerich, J. E., Schultz, T. A., Lewis, S. B., & Karam, J. H. (1977) · Diabetologia · doi:10.1007/bf01234510 · Cited by 66
Self-citationStudies of the Physiologic Role of Glucagon
Unger, R. H., & Eisentraut, A. M. (1964) · Diabetes · doi:10.2337/diab.13.6.563 · Cited by 65
Ryan, A. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2399 · Cited by 65
Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565120-00008 · Cited by 64
Glucagon as a target for the treatment of Type 2 diabetes
Sloop, K. W., Michael, M. D., & Moyers, J. S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.593 · Cited by 63
Mitani, H., Takimoto, M., Hughes, T. E., & Kimura, M. (2002) · Japanese Journal of Pharmacology · doi:10.1254/jjp.88.442 · Cited by 63
Minimal Increases in Glucagon Levels Enhance Glucose Production in Man with Partial Hypoinsulinemia
Lins, P.-E., Wajngot, A., Adamson, U., Vranic, M., & Efendić, S. (1983) · Diabetes · doi:10.2337/diab.32.7.633 · Cited by 62
Metabolic abnormalities in impaired glucose tolerance
Gerich, J. E. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90316-4 · Cited by 61
Self-citationRole of the Decrement in Intraislet Insulin for the Glucagon Response to Hypoglycemia in Humans
Gosmanov, N. R., Szoke, E., Israelian, Z., Smith, T., Cryer, P. E., Gerich, J. E., & Meyer, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1124 · Cited by 61
Self-citationApplications of dipeptidyl peptidase IV inhibitors in diabetes mellitus
McIntosh, C. H. S., Demuth, H., Kim, S.-J., Pospisilik, J. A., & Pederson, R. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.013 · Cited by 58
Mentlein, R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.57 · Cited by 58
Abnormal alpha cell function in human diabetes
Raskin, P., Aydin, İ., Yamamoto, T., & Unger, R. H. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90454-0 · Cited by 57
Shamoon, H., Friedman, S., Canton, C., Zacharowicz, L., Hu, M., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117267 · Cited by 57
Glucagon Treatment of Insulin Reactions
Elrick, H., Witten, T. A., & Arai, Y. (1958) · New England Journal of Medicine · doi:10.1056/nejm195803062581005 · Cited by 55
Raskin, P., & Unger, R. H. (1978) · Diabetes · doi:10.2337/diab.27.4.411 · Cited by 54
Renal Compensation for Impaired Hepatic Glucose Release During Hypoglycemia in Type 2 Diabetes
Woerle, H. J., Meyer, C., Popa, E. M., Cryer, P. E., & Gerich, J. E. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1386 · Cited by 52
Self-citationGerich, J. E. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90584-2 · Cited by 50
Self-citationAbnormal Response of Pancreatic Glucagon to Glycemic Changes in Diabetes Mellitus
OHNEDA, A., WANTANABE, K., HORIGOME, K., SAKAI, T., KAI, Y., & OIKAWA, S.-I. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-3-504 · Cited by 49
Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans
Lecavalier, L., Bolli, G., & Gerich, J. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.4.e569 · Cited by 48
Self-citationHolste, L. C., Connolly, C. C., Moore, M. C., Neal, D. W., & Cherrington, A. D. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.3.e488 · Cited by 48
Studies on the Perfused Rat Liver: I. Effects of Glucagon and Insulin on Glucose Metabolism
Williamson, J. R., Garcia, A., Renold, A. E., & Cahill, G. F. (1966) · Diabetes · doi:10.2337/diab.15.3.183 · Cited by 45
Effects of Type 2 Diabetes on the Regulation of Hepatic Glucose Metabolism
Basu, A., Shah, P., Nielsen, M., Basu, R., & Rizza, R. (2004) · Journal of Investigative Medicine · doi:10.1136/jim-52-06-30 · Cited by 44
Gill, I., & Patel, R. N. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.021 · Cited by 44
Heller, S. R., Macdonald, I. A., & Tattersall, R. B. (1987) · Diabetologia · doi:10.1007/bf00295875 · Cited by 43
Moldovan, S., Atiya, A., Adrian, T. E., Kleinman, R. M., Lloyd, K. C. K., Olthoff, K. M., Imagawa, D. K., Shevlin, L., Coy, D. H., Walsh, J. H., et al. (1995) · Journal of Surgical Research · doi:10.1006/jsre.1995.1136 · Cited by 43
Oxidative stress: The special case of diabetes
Wiernsperger, N. F. (2003) · BioFactors · doi:10.1002/biof.5520190103 · Cited by 43
Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists
Ling, A., Hong, Y., Gonzalez, J., Gregor, V., Polinsky, A., Kuki, A., Shi, S., Teston, K., Murphy, D., Porter, J., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000547o · Cited by 42
Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?
Raju, B., & Cryer, P. E. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2004 · Cited by 42
Borghi, V. C., Wajchenberg, B. L., & CESAR, F. P. (1984) · Metabolism · doi:10.1016/0026-0495(84)90089-1 · Cited by 40
Dallas-Yang, Q., Shen, X., Strowski, M. Z., Brady, E. J., Saperstein, R., Gibson, R. E., Szalkowski, D., Qureshi, S. A., Candelore, M. R., Fenyk-Melody, J. E., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.023 · Cited by 40
Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance
Larsson, H. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.6.1778 · Cited by 40
Human glucagon receptor antagonists based on alkylidene hydrazides
Ling, A. L., Plewe, M. B., González, J., Madsen, P., Sams, C. K., Lau, J. F., Gregor, V. E., Murphy, D., Teston, K., Kuki, A., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00819-8 · Cited by 40
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists
Shen, D., Zhang, F., Brady, E. J., Candelore, M. R., Dallas-Yang, Q., Ding, V. D. H., Dragovic, J., Feeney, W. P., Jiang, G., McCann, P. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.101 · Cited by 40
Deacon, C. F. (2005) · PubMed · Cited by 39
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Triplitt, C. L., Wright, A., & Chiquette, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.360 · Cited by 38
Glucose Modulation of Insulin and Glucagon Secretion in Nondiabetic and Diabetic Man
Hollander, P. M., Asplin, C. M., & Palmer, J. P. (1982) · Diabetes · doi:10.2337/diab.31.6.489 · Cited by 38
Day-long Subcutaneous Infusion of Exenatide Lowers Glycemia in Patients with Type 2 Diabetes
Taylor, K., Kim, D., Nielsen, L. L., Aisporna, M., Baron, A. D., & Fineman, M. S. (2005) · Hormone and Metabolic Research · doi:10.1055/s-2005-870529 · Cited by 38
Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists
Ladouceur, G. H., Cook, J. H., Doherty, E. M., Schoen, W. R., MacDougall, M. L., & Livingston, J. N. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00766-1 · Cited by 37
Chapter 19. DPP-IV inhibition and therapeutic potential
Villhauer, E. B., Coppola, G. M., & Hughes, T. E. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36059-1 · Cited by 36
Kim, K.-R., Rhee, S.-D., Kim, H. Y., Jung, W. H., Yang, S., Kim, S. S., Ahn, J. H., & Cheon, H. G. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.030 · Cited by 36
Sherwin, R. S., Tamborlane, W., Hendler, R., Saccá, L., DeFronzo, R. A., & Felig, P. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-5-1104 · Cited by 36
Van Tine, B. A. (1996) · Endocrinology · doi:10.1210/en.137.8.3316 · Cited by 36
[The effects of perfusion and amino acid ingestion in glucagonenemia].
Assan, R., Rosselin, G., & Dolais, J. (1967) · PubMed · Cited by 36
Assan, R., Hautecouverture, G., Guillemant, S., Dauchy, F., Protin, P., & Dérot, M. (1969) · PubMed · Cited by 36
Hamaguchi, T., Fukushima, H., Uehara, M., Wada, S., Shirotani, T., Kishikawa, H., Ichinose, K., Yamaguchi, K., & Shichiri, M. (1991) · Diabetologia · doi:10.1007/bf00408354 · Cited by 35
Hepatorenal glucose reciprocity in physiologic and pathologic conditions.
Gerich, J. E. (2002) · PubMed · Cited by 34
Self-citationSakashita, H., Kitajima, H., Nakamura, M., Akahoshi, F., & Hayashi, Y. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.077 · Cited by 33
K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent
Takasaki, K., Iwase, M., Nakajima, T., Ueno, K., Nomoto, Y., Nakanishi, S., & Higo, K. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.029 · Cited by 33
Boushey, R. P., Abadir, A., Flamez, D., Baggio, L. L., Li, Y., Berger, V., Marshall, B. A., Finegood, D. T., Wang, T. C., Schuit, F. C., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01195-8 · Cited by 32
Pancreatic and extrapancreatic effects of GLP-1.
Valverde, I., Villanueva-Peñacarrillo, M., & Malaisse, W. J. (2002) · PubMed · Cited by 31
Sakashita, H., Akahoshi, F., Kitajima, H., Tsutsumiuchi, R., & Hayashi, Y. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.01.022 · Cited by 31
Dimitriadis, G. D., Pehling, G. B., & Gerich, J. E. (1985) · Diabetes · doi:10.2337/diab.34.6.541 · Cited by 31
Self-citationARONOFF, S. L., BENNETT, P. H., & UNGER, R. H. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-44-5-968 · Cited by 30
Barnett, A. (2005) · Drugs of Today · doi:10.1358/dot.2005.41.9.893704 · Cited by 30
Control of Glucose Production in vivo by Insulin and Glucagon
Cherrington, A. D. (2001) · Comprehensive Physiology · doi:10.1002/cphy.cp070225 · Cited by 29
Gysin, B., Johnson, D. G., Trivedi, D. B., & Hruby, V. J. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00391a024 · Cited by 28
Mitani, H., Takimoto, M., & Kimura, M. (2002) · Japanese Journal of Pharmacology · doi:10.1254/jjp.88.451 · Cited by 28
LILJENQUIST, J. E., Bloomgarden, Z. T., Cherrington, A. D., Perry, J., & Rabin, D. U. (1979) · Diabetologia · doi:10.1007/bf01219739 · Cited by 27
Regulation of hepatic glucose output by glucose in vivo
Müller, M. J., Möring, J., & Seitz, H. J. (1988) · Metabolism · doi:10.1016/0026-0495(88)90029-7 · Cited by 27
Hormonal responses to insulin infusion in diabetes mellitus
Campbell, L. V., Kraegen, E. W., Meler, H., & Lazarus, L. (1979) · Diabetologia · doi:10.1007/bf01223155 · Cited by 27
Advances in Non-Peptide Glucagon Receptor Antagonists
Madsen, P., Brand, C. L., Holst, J. J., & Knudsen, L. B. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230111194905 · Cited by 27
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
Metabolic effects of long-term somatostatin infusion in man
Gerich, J. E. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80179-5 · Cited by 25
Self-citationTakasaki, K., Nakajima, T., Ueno, K., Nomoto, Y., & Higo, K. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.sc0040043 · Cited by 25
Synthetic glucagon antagonists and partial agonists
Zechel, C., Trivedi, D. B., & Hruby, V. J. (1991) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1991.tb01420.x · Cited by 25
Development of Potent Truncated Glucagon Antagonists
Ahn, J.-M., Medeiros, M. K., Trivedi, D. B., & Hruby, V. J. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000453e · Cited by 24
Berenson, G. S., Bao, W., & Srinivasan, S. R. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008866 · Cited by 24
Raskin, P., & Unger, R. H. (1978) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31767-9 · Cited by 24
Glucagon receptor antagonists for the treatment of type II diabetes: current prospects.
Djurić, S. W., Grihalde, N. D., & Lin, C. W. (2002) · PubMed · Cited by 24
Gerich, J. E. (1981) · PubMed · Cited by 23
Self-citationAhn, J.-M., Medeiros, M., Trivedi, D., & Hruby, V. J. (2001) · Journal of Peptide Research · doi:10.1034/j.1399-3011.2001.00880.x · Cited by 23
Glucagon antagonists: Synthesis and inhibitory properties of Asp3‐containing glucagon analogs
Andreu, D., & Merrifield, R. B. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb11167.x · Cited by 23
THE DESTRUCTION OF GLUCAGON BY THE BLOOD PLASMA FROM VARIOUS SPECIES1
Mirsky, I. A., Perisutti, G., & Davis, N. C. (1959) · Endocrinology · doi:10.1210/endo-64-6-992 · Cited by 23
Effects of Type 2 Diabetes on the Regulation of Hepatic Glucose Metabolism
Basu, A., Shah, P., Nielsen, M. F., Basu, R., & Rizza, R. A. (2004) · Journal of Investigative Medicine · doi:10.1177/108155890405200630 · Cited by 23
Raju, B., & Cryer, P. E. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00188.2004 · Cited by 22
Small-molecule glucagon receptor antagonists
Ling, A. (2002) · Drugs of the Future · doi:10.1358/dof.2002.027.10.701362 · Cited by 21
Bringer, J., Mirouze, J., Marchal, G., Pham, T. C., LUYCKX, A. S., Lefebvre, P., & Orsetti, A. (1981) · Diabetes · doi:10.2337/diab.30.10.851 · Cited by 20
The GLP‐1 system as a therapeutic target
Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19
(1977) · doi:10.1001/archinte.1977.03630170067016 · Cited by 19
Self-citationABNORMAL PANCREATIC ALPHA-CELL FUNCTION IN FIRST-DEGREE RELATIVES OF KNOWN DIABETICS.
Kirk, R. D., Dunn, P. J., Smith, J. R., BEAVEN, D. W., & Donald, R. A. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-40-5-913 · Cited by 18
WARD, W. K., BEST, J. D., HALTER, J. B., & PORTE, D. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-3-449 · Cited by 18
Autoregulation of endogenous glucose production during hyperglucagonemia
Toft, I., Gerich, J. E., & Jenssen, T. G. (2002) · Metabolism · doi:10.1053/meta.2002.34702 · Cited by 17
Self-citationSynthetic linear and cyclic glucagon antagonists
DHARANIPRAGADA, R., Trivedi, D. B., BANNISTER, A., SIEYEL, M., Tourwé, D., Mollova, N. N., Schram, K. H., & Hruby, V. J. (1993) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1993.tb00352.x · Cited by 17
Bajorunas, D. R., Fortner, J. G., & Jaspan, J. B. (1986) · Diabetes · doi:10.2337/diab.35.8.886 · Cited by 15
Cohen, S. M., Duffy, J. L., Miller, C. O., Kirk, B. A., Candelore, M. R., Ding, V. D. H., Kaczorowski, G. J., Tota, L. M., Werrmann, J. G., Wright, M., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.10.008 · Cited by 15
Insulin-Glucagon Interaction in Controlling Splanchnic Glucose Production in Norma Man
Bomboy, J. D., Lewis, S. B., SINCLAIR-SMITH, B. C., LACY, W. W., & LILJENQUIST, J. E. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-44-3-474 · Cited by 15
Gomis, R., Novials, A., Coves, M. J., Casamitjana, R., & Malaisse, W. J. (1989) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(89)90029-6 · Cited by 15
Evanescent effects of hypo- and hyperglucagonemia on blood glucose homeostasis
Sherwin, R., Wahren, J., & Felig, P. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80146-1 · Cited by 15
Wargent, E. T., Stocker, C. J., Augstein, P., Heinke, P., Meyer, A., Hoffmann, T., Subramanian, A., Sennitt, M. V., Demuth, H., Arch, J. R. S., et al. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00383.x · Cited by 15
Physiology of GLP-1 - Lessons from Glucoincretin Receptor Knockout Mice
Thorens, B. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826161 · Cited by 13
Ladouceur, G. H., Cook, J. H., Hertzog, D. L., Jones, J., Hundertmark, T., Korpusik, M., Lease, T. G., Livingston, J. N., MacDougall, M. L., Osterhout, M. H., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00736-9 · Cited by 13
Azizeh, B. Y., Tine, B. A. V., Trivedi, D. B., & Hruby, V. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00131-9 · Cited by 12
THE AMERICAN PHYSIOLOGICAL SOCIETY
Jester, A., Frank, M., Mccarter, K., & Newton, K. (1906) · Science · doi:10.1126/science.23.576.76 · Cited by 12
ROLE OF GLUCAGON IN HUMAN DIABETIC KETOACIDOSIS: STUDIES USING SOMATOSTATIN
Gerich, J. E., Schneider, V. S., Lorenzi, M., Tsalikian, E., Karam, J. H., Bier, D. M., & Forsham, P. H. (1976) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1976.tb03838.x · Cited by 11
Self-citationResponses of the pancreatic A cell during hypoglycemia and hyperglycemia are dependent on the B cell
McCulloch, D. K., Raghu, P., Koerker, D. J., Palmer, J. P., & Klaff, L. J. (1989) · Metabolism · doi:10.1016/0026-0495(89)90111-x · Cited by 11
Evidence that hyperglycaemia per se does not inhibit hepatic glucose production in man
M�ller, M. J., Acheson, K. J., Burger, A., & Jéquier, E. (1990) · European Journal of Applied Physiology · doi:10.1007/bf00379399 · Cited by 10
Somatostatin Therapy in the Management of Resistant Diabetic Ketoacidosis
Boşnak, M., Dikici, B., Doğru, Ö., Davutoğlu, M., & Haspolat, K. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.629 · Cited by 10
Impaired Glucose Tolerance and Glucosuria Induced in Man by Repeated Injections of Glucagon
Itallie, T. B. V., Jp, F., Hoet, J. J., & Renold, A. E. (1959) · Diabetes · doi:10.2337/diab.8.2.94 · Cited by 10
Dipeptidyl peptidase IV inhibitors
Evans, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00073-1 · Cited by 9
Evidence for an insulin-independent alpha-cell abnormality in human diabetes
Bennett, P. H., Aronoff, S. L., & Unger, R. H. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80185-0 · Cited by 8
Abs, R., Verbist, L., Moeremans, M., Blockx, P. P., Leeuw, I. D., & Bekaert, J. (1990) · European Journal of Endocrinology · doi:10.1530/acta.0.1220319 · Cited by 8
Takasaki, K., Takada, H., Nakajima, T., Ueno, K., Ushiki, J., & Higo, K. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.018 · Cited by 7
The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes
Schnabel, C. A. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050040801 · Cited by 5
Somatostatin: A tool for investigation of the metabolic effects of cortisol and glucagon
Johnston, D. G., Gill, A., Hanson, R., Alberti, K. G. M. M., Batstone, G. F., & Ørskov, H. (1978) · Metabolism · doi:10.1016/0026-0495(78)90090-2 · Cited by 3
Al-Omar, M. A., & Al-Arifi, M. N. (2005) · Saudi Medical Journal · doi:10.15537/1658-3175.3143 · Cited by 2
Exenatide: A Viewpoint by Curtis Triplitt and Ralph A. DeFronzo
Triplitt, C. L., & DeFronzo, R. A. (2005) · Drugs · doi:10.2165/00003495-200565120-00009 · Cited by 1
Exenatide: A viewpoint by Curtis Triplitt and Ralph
DeFronzo, A., & Rosenstock, J. (2005) · Drugs · Cited by 1
Research works printed but not linked: 9
- 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
- 2005, Byetta (exenatide injection)[prescribing information].
- Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
- Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
- Balas, J Clin Endocrinol Metab
- Dejager, Horm Metab Res
- Bosi, Diabetes Care
- Rosenstock, Diabetes Obes Metab
- Garber, Diabetes Obes Metab
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
“This relative hyperglucagonaemia aggravates the consequences of their relative hypoinsulinaemia by activating glucose production in the liver [8–10].”
BackgroundEvidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A. H., Kirkpatrick, C. L., Wollheim, C. B., Eliasson, L., Rönn, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004160 · Cited by 523
“Since both decreased insulin and increased glucagon secretion from pancreatic islets are known to contribute to hyperglycemia in patients with T2D [49], we investigated whether the identified candidate genes also affect glucagon secretion in clonal a-cells.”
Metadata
- Authors
- Dunning, B. E., & Gerich, J. E.
- Affiliations
- PharmaWrite, Princeton, New Jersey 08540
- University of Rochester Medicine (US)
- Corresponding author
- Gerich, John E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-04-04
- Volume
- 28
- Issue
- 3
- Pages
- 253-283
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2088987697
- Cited by
- 369
- References
- 323
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- University of Rochester
- Kowa Company
- Eisai
- Novo Nordisk
- Medical Center, University of Rochester
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.